Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
NCT03246906 · Fred Hutchinson Cancer Center · PHASE2 · terminated · last registry update 2026-05-14 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.” | – | Registry record, Fred Hutchinson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPIA in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-20Also stopped (terminated): Masonic Cancer Center, University of Minnesota, Fludarabine + Cyclophosphamide (NCT01962636)
- 2026-01-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Cyclosporine A (CsA) + Sirolimus (NCT07366801)
- 2025-08-26Results posted on the registry: Masonic Cancer Center, University of Minnesota, filgrastim + busulfan (NCT00357565)
- 2025-07-10Phase 3 first posted: Shanxi Bethune Hospital, Induction Therapy Regimen + Pre-Treatment Regimen (NCT07059156)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision